GLC Medical (GLCM) Inc.
Completes Development of Virus Detection Platform
EDMONTON, AB, May 11, 2022 – GLC Medical (GLCM) Inc. is pleased to announce that it has completed the development of its GLCM Biosensor Test Platform, which produces results in under one-minute. The biosensor, in the process of regulatory approval, can be tailored to detect multiple viruses and other pathogens and represents a global breakthrough in medical diagnostics by providing real-time virus detection that is unmatched in terms of sensitivity, simplicity, and reproducibility by utilizing electrochemical impedance spectroscopy (EIS). Successful implementation of the EIS method, which has been researched over decades as a desirable method of testing, is a breakthrough for GLCM and the medical diagnostics industry.